

Barcelona, April 1st 2019

SIGNIFICANT EVENT

Almirall divests ThermiGen, its medical device aesthetics business, and completes its strategic reorientation towards medical dermatology

Almirall, S.A. (ALM.MC), as per section 228 of the Royal Legislative Decree 4/2015, of 23 October 2015, approving the Restated Text of the Securities Market Act, hereby announces that:

Almirall entered into a definitive agreement with Celling Biosciences to divest ThermiGen for an undisclosed amount last 4th March.

Today, Almirall announced that it has closed the divestment of ThermiGen to Celling Biosciences.

The transaction announced does not affect Almirall Guidance for 2019 year, which was published on February 25th, 2019.

Yours sincerely,

Pablo Divasson del Fraile
Investor Relations & Corporate Comms. Department
investors@almirall.com